Across TCGA pan-cancer cohorts, MIR323B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR323B data layer compared with 12 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MIR323B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR323B expression acts as an unfavorable survival marker.
SKCM are the cancer types where MIR323B Mutation most reproducibly stratifies survival.